Newlink Genetics Corporation

Central Iowa Health System

Iowa Health System

Gabriela Rossi

Charles J Link

Firoz Jaipuri

Mario Mautino

Charles J Link, Jr

Nicholas N Vahanian

Tatiana Seregina

Won-Bin Young

The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce &#x3b1;Gal epitopes or &#x3b1;Gal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-&#x3b1;Gal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.

Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes

The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an &#x3b1;(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The &#x3b1;-galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.

Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase

The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an &#x3b1;(1,3)galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The &#x3b1; galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.

The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an &#x3b1; (1,3) galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The &#x3b1; galactosyl epitope causes opsonization of the tumor cell enhancing uptake of the opsonized tumor cell by antigen presenting cells which results in enhanced tumor specific antigen presentation. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.

The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce &#x3b1;Gal epi topes or &#x3b1;Gal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-&#x3b1;Gal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.

Growing community of inventors

Ankeny, IA, United States of America

Gabriela Rossi